{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T15:37:56Z","timestamp":1726760276419},"reference-count":29,"publisher":"Societas Neurologica Japonica","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rinsho Shinkeigaku"],"published-print":{"date-parts":[[2015]]},"DOI":"10.5692\/clinicalneurol.55.227","type":"journal-article","created":{"date-parts":[[2015,4,21]],"date-time":"2015-04-21T18:03:08Z","timestamp":1429639388000},"page":"227-232","source":"Crossref","is-referenced-by-count":3,"title":["A case of refractory generalized myasthenia gravis with anti-acetylcholine receptor antibodies treated with rituximab"],"prefix":"10.5692","volume":"55","author":[{"given":"Ryutaro","family":"Hayashi","sequence":"first","affiliation":[{"name":"Clinical Research Institute, Utano National Hospital"},{"name":"Department of Neurology, Utano National Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Tahara","sequence":"additional","affiliation":[{"name":"Clinical Research Institute, Utano National Hospital"},{"name":"Department of Neurology, Utano National Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Oeda","sequence":"additional","affiliation":[{"name":"Clinical Research Institute, Utano National Hospital"},{"name":"Department of Neurology, Utano National Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuro","family":"Konishi","sequence":"additional","affiliation":[{"name":"Present Address: Gakusai Hospital"},{"name":"Department of Neurology, Utano National Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideyuki","family":"Sawada","sequence":"additional","affiliation":[{"name":"Clinical Research Institute, Utano National Hospital"},{"name":"Department of Neurology, Utano National Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3663","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Zaja F, Russo D, Fuga G, et al. Rituximab for myasthenia gravis developing after bone marrow transplant. Neurology 2000;55:1062-1063.","DOI":"10.1212\/WNL.55.7.1062-a"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Wylam ME, Anderson PM, Kuntz NL, et al. Successful treatment of refractory myasthenia gravis using rituximab: a pediatric case report. J Pediatr 2003;143:674-677.","DOI":"10.1067\/S0022-3476(03)00300-7"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Lebrun C, Bourg V, Tieulie N, et al. Successful treatment of refractory generalized myasthenia gravis with rituximab. Eur J Neurol 2009;16:246-250.","DOI":"10.1111\/j.1468-1331.2008.02399.x"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Nelson RP Jr, Pascuzzi RM, Kessler K, et al. Rituximab for the treatment of thymoma-associated and de novo myasthenia gravis: 3 cases and review. J Clin Neuromuscul Dis 2009;10:170-177.","DOI":"10.1097\/CND.0b013e31819a8403"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Blum S, Gillis D, Brown H, et al. Use and monitoring of low dose rituximab in myasthenia gravis. J Neurol Neurosurg Psychiatry 2011;82:659-663.","DOI":"10.1136\/jnnp.2010.220475"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Ibrahim H, Dimachkie MM, Shaibani A. A review: the use of rituximab in neuromuscular diseases. J Clin Neuromuscul Dis 2010;12:91-102.","DOI":"10.1097\/CND.0b013e3181ff49f3"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) St\u00fcbgen JP. B cell-targeted therapy with rituximab and autoimmune neuromuscular disorders. J Neuroimmunol 2008;204:1-12.","DOI":"10.1016\/j.jneuroim.2008.07.019"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Venhoff N, Effelsberg NM, Salzer U, et al. Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides. PLoS One 2012;7:e37626.","DOI":"10.1371\/journal.pone.0037626"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Irie E, Shirota Y, Suzuki C, et al. Severe hypogammaglobulinemia persisting for 6 years after treatment with rituximab combined chemotherapy due to arrest of B lymphocyte differentiation together with alteration of T lymphocyte homeostasis. Int J Hematol 2010;9:501-508.","DOI":"10.1007\/s12185-010-0528-6"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Walker AR, Kleiner A, Rich L, et al. Profound hypogammaglobulinemia 7 years after treatment for indolent lymphoma. Cancer Invest 2008;26:431-433.","DOI":"10.1080\/07357900701809068"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Gajra A, Vajpayee N, Grethlein SJ. Response of myasthenia gravis to rituximab in a patient with non-Hodgkin lymphoma. Am J Hematol 2004;77:196-197.","DOI":"10.1002\/ajh.20169"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Lin PT, Martin BA, Weinacker AB, et al. High-dose cyclophosphamide in refractory myasthenia gravis with MuSK antibodies. Muscle Nerve 2006;33:433-435.","DOI":"10.1002\/mus.20411"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Hain B, Jordan K, Deschauer M, et al. Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab. Muscle Nerve 2006;33:575-580.","DOI":"10.1002\/mus.20479"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) D\u00edaz-Manera J, Rojas-Garc\u00eda R, Gallardo E, et al. Antibodies to AChR, MuSK and VGKC in a patient with myasthenia gravis and Morvan\u2019s syndrome. Nat Clin Pract Neurol 2007;3:405-410.","DOI":"10.1038\/ncpneuro0526"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Thakre M, Inshasi J, Marashi M. Rituximab in refractory MuSK antibody myasthenia gravis. J Neurol 2007;254:968-969.","DOI":"10.1007\/s00415-006-0442-2"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Baek WS, Bashey A, Sheean GL. Complete remission induced by rituximab in refractory, seronegative, muscle-specific, kinase-positive myasthenia gravis. J Neurol Neurosurg Psychiatry 2007;78:771.","DOI":"10.1136\/jnnp.2006.093567"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Illa I, Diaz-Manera J, Rojas-Garcia R, et al. Sustained response to Rituximab in anti-AChR and anti-MuSK positive Myasthenia Gravis patients. J Neuroimmunol 2008;201-202:90-94.","DOI":"10.1016\/j.jneuroim.2008.04.039"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Kerkeni S, Marotte H, Miossec P. Improvement with rituximab in a patient with both rheumatoid arthritis and myasthenia gravis. Muscle Nerve 2008;38:1343-1345.","DOI":"10.1002\/mus.21047"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Evoli A, Bianchi MR, Riso R, et al. Response to therapy in myasthenia gravis with anti-MuSK antibodies. Ann N Y Acad Sci 2008;1132:76-83.","DOI":"10.1196\/annals.1405.012"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Stieglbauer K, Topakian R, Sch\u00e4ffer V, et al. Rituximab for myasthenia gravis: three case reports and review of the literature. J Neurol Sci 2009;280:120-122.","DOI":"10.1016\/j.jns.2009.02.357"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Zebardast N, Patwa HS, Novella SP, et al. Rituximab in the management of refractory myasthenia gravis. Muscle Nerve 2010;41:375-378.","DOI":"10.1002\/mus.21521"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Lindberg C, Bokarewa M. Rituximab for severe myasthenia gravis\u2014experience from five patients. Acta Neurol Scand 2010;122:225-228.","DOI":"10.1111\/j.1600-0404.2010.01345.x"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Maddison P, McConville J, Farrugia ME, et al. The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 2011;82:671-673.","DOI":"10.1136\/jnnp.2009.197632"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Nowak RJ, Dicapua DB, Zebardast N, et al. Response of patients with refractory myasthenia gravis to rituximab: a retrospective study. Ther Adv Neurol Disord 2011;4:259-266.","DOI":"10.1177\/1756285611411503"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Guptill JT, Sanders DB. Update on muscle-specific tyrosine kinase antibody positive myasthenia gravis. Curr Opin Neurol 2010;23:530-535.","DOI":"10.1097\/WCO.0b013e32833c0982"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Burusnukul P, Brennan TD, Cupler EJ. Prolonged improvement after rituximab: two cases of resistant muscle-specific receptor tyrosine kinase + myasthenia gravis. J Clin Neuromuscul Dis 2010;12:85-87.","DOI":"10.1097\/CND.0b013e3181fcc109"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Stein B, Bird SJ. Rituximab in the treatment of MuSK antibody-positive myasthenia gravis. J Clin Neuromuscul Dis 2011;12:163-164.","DOI":"10.1097\/CND.0b013e3181df2b3e"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Guptill JT, Sanders DB, Evoli A. Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts. Muscle Nerve 2011;44:36-40.","DOI":"10.1002\/mus.22006"},{"key":"29","unstructured":"29) Jaretzki A 3rd, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 2000;55:16-23."}],"container-title":["Rinsho Shinkeigaku"],"original-title":["\u6cbb\u7642\u62b5\u6297\u6027\u306e\u6297\u30a2\u30bb\u30c1\u30eb\u30b3\u30ea\u30f3\u53d7\u5bb9\u4f53\u6297\u4f53\u967d\u6027\u91cd\u75c7\u7b4b\u7121\u529b\u75c7\u306b\u5bfe\u3057rituximab\u3092\u6295\u4e0e\u3057\u305f1\u4f8b"],"language":"en","deposited":{"date-parts":[[2019,8,23]],"date-time":"2019-08-23T18:20:10Z","timestamp":1566584410000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/clinicalneurol\/55\/4\/55_227\/_article\/-char\/ja\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.5692\/clinicalneurol.55.227","relation":{},"ISSN":["0009-918X","1882-0654"],"issn-type":[{"value":"0009-918X","type":"print"},{"value":"1882-0654","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015]]}}}